Rapamycin, a medicine given to transplant patients, improved brain blood flow in middle-aged carriers of the APOE4 gene variant, researchers in Missouri report.
What if one of the earliest warning signs of Alzheimer's disease is not a lost name or a forgotten key, but a slow trickle of blood? That is the idea driving Ai-Ling Lin, a professor in the School of Medicine at the University of Missouri. She studies APOE4, a gene variant that substantially raises the risk of Alzheimer's later in life. People who carry it can show reduced blood flow in certain brain regions years before any memory trouble appears.
The circulation, in other words, may falter long before the mind does. So Lin's team tried something unexpected. They turned to rapamycin, a drug that doctors already use to stop the body from rejecting transplanted organs and to treat some rare conditions. It was first associated with surgery wards, not memory clinics.
Yet scientists on several continents have also been studying it as a possible brake on biological aging. Before moving to Missouri, Lin had tested it in mice carrying APOE4. The animals showed slower brain aging and better blood flow. The obvious next question was whether humans would respond in the same way.